Related Experiment Video
Updated: Jun 20, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Effects of cancer drugs on survival: often poorly evaluated
Abstract:
(1) Overall survival is the gold-standard endpoint when evaluating the efficacy of cancer drugs; (2) Progression-free survival is an endpoint that combines two very different components: death or objective worsening of the tumour. It is a heterogeneous endpoint and measurement of the second component is imprecise. There are few examples where a correlation has been established between progression-free survival and overall survival; (3) Time to progression is an endpoint of limited interest: it only takes into account the second component of the progression-free survival composite endpoint; (4) Disease-free survival is a variant of progression-free survival and is most frequently used for adjuvant treatments.
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
